Cipla per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹35.87₹48.03₹65.29₹51.05₹34.72
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹35.83₹48.00₹65.24₹51.01₹34.69
₹426.24₹426.24₹386.25₹330.79₹290.01
₹348.34₹348.63₹341.10₹319.24₹281.89
—₹48.77₹61.97₹51.20₹40.11
₹10.65₹10.65₹42.80₹34.49₹25.46
—₹16.00₹13.00₹8.50₹5.00
80.880.880.880.780.7
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CIPLA₹1,365.60

Cipla Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYLUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹1.10L Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS34.7251.0565.2948.0335.87
Diluted EPS34.6951.0165.2448.0035.83
Book Value per Share290.01330.79386.25426.24426.24
Revenue per Share281.89319.24341.10348.63348.34
Cash Flow per Share40.1151.2061.9748.77—
Free Cash Flow per Share25.4634.4942.8010.6510.65
Dividends per Share5.008.5013.0016.00—
Shares Outstanding (cr)80.780.780.880.880.8
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 146%.